Herceptin after breast surgery with less chemotherapy
Treatments studied
Part of Cancer clinical trials.
This trial looks at whether Herceptin (trastuzumab) can be used as after-treatment with less chemotherapy for certain early breast cancers. It may help reduce how much chemotherapy you need, while still lowering the chance the cancer comes back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed breast cancer that has not spread to other organs (non-metastatic).
- The tumor was not removed by surgery yet (non-operated tumor).
- Your lymph node exam shows no suspicious under-arm (axillary) lymph nodes.
- Your tumor is smaller than 3 cm (30 mm).
- Your tumor tests show HER-2 is high (3+ on one test, or 2+ with a confirm test like FISH/CISH).
- Your heart pumping strength is okay, with a measured value above 50% around 3 months (by echocardiogram or similar heart scan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
This trial tests whether giving trastuzumab before surgery can improve outcomes for people with HER2-positive early breast cancer. Trastuzumab is a targeted medicine that helps treat HER2-driven cancer before the tumor is removed.
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
This trial tests a new drug called trastuzumab rezetecan given before surgery for early-stage HER2-positive breast cancer. It's designed for patients whose cancer doesn't respond well to standard HER2-targeted treatments.
This Phase 2 trial studies a second anti-HER2 treatment (given after surgery) to help lower the risk of breast cancer coming back in people with very small, node-negative, HER2-positive tumors. It will also closely monitor heart function and other side effects because these medicines can affect the body.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.